Skip to main content
. 2022 Jan 27;27(3):880. doi: 10.3390/molecules27030880

Figure 3.

Figure 3

Inhibition of relative growth by MHI-palbociclib is significantly higher than the parent compound palbociclib, or the combination of palbociclib with unconjugated MHI-148 in breast cancer MCF-7 and MDA-MB-231 cell lines. Effects on breast cancer cell lines were measured after 3 days exposure to the compounds. Data presented are an average of at least three independent experiments, * p < 0.05.